)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MBX Biosciences
MBX Biosciences (MBX) investor relations material
MBX Biosciences Stifel 2026 Virtual Cardiometabolic Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Stifel 2026 Virtual Cardiometabolic Forum summary30 Sep, 2026
Strategic overview and pipeline updates
Precision endocrine peptide platform enables customized peptides with improved potency, durability, and infusion-like PK profiles for differentiated clinical outcomes.
Lead asset canvuparatide is in phase III for chronic hypoparathyroidism, following successful phase II results showing normalization of serum and urine calcium and improved bone turnover.
Obesity portfolio includes MBX 4291 (once-monthly GLP-1/GIP co-agonist in phase I), MBX 5765 (amycretin), and MBX 6180 (triple G), with the latter two expected to enter the clinic next year.
Company is well-capitalized with $420 million in cash, providing runway into 2029 and supporting advancement of multiple programs.
Clinical development highlights
Canvuparatide phase II demonstrated durable normalization of serum calcium, reduced urine calcium in high-risk patients, and improved bone markers, supporting a best-in-class weekly PTH replacement profile.
Phase III for canvuparatide starts at 600 mcg with titration from 400–1,600 mcg, aiming to validate phase II results and capture both serum and urine calcium normalization as endpoints.
Physician and patient feedback highlights strong preference for once-weekly dosing due to convenience and potential for switching from daily injectables.
Enrollment for canvuparatide phase III expected to complete in H2 2027, with primary endpoint readout likely in H1 2028.
Obesity program differentiation and outlook
MBX 4291 features a slow, steady PK profile, minimizing burst effects and GI intolerability, with true once-monthly dosing potential (Tmax 26 days).
Early blinded data show promising tolerability (minimal GI side effects) and weight loss (~7% at 8 weeks), with unblinded cohort C1 data expected in Q4.
Dose escalation to 180 mg is exploratory, with titration schema designed to mitigate tolerability issues.
Manufacturing costs for MBX 4291 expected to be commercially feasible, with auto-injector development planned for phase III.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MBX Biosciences
- Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027.MBX
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 net loss rose to $37.1M as R&D spending increased; cash reserves support operations into 2029.MBXQ2 2026
- Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum.MBXCorporate presentation
- Phase III for once-weekly canvuparatide starts Q3 2024, with major 2026 data and strong financials.MBXPiper Sandler 37th Annual Healthcare Conference
- Once-weekly canvuparatide showed durable efficacy and safety at one year, supporting Phase III advancement.MBXStudy result
- All director and auditor proposals were approved by stockholders at the annual meeting.MBXAGM 2026
- Advancing once-weekly and monthly therapies for obesity and hypoparathyroidism with key data ahead.MBXJefferies Global Healthcare Conference 2026
- Once-monthly MBX 4291 achieved 7% weight loss and strong tolerability in phase I.MBXStatus update
- Audit Committee and board changes, plus new consulting agreement with equity awards.MBXProxy filing
Next MBX Biosciences earnings date
Q3 20266 Nov, 2026
MBX Biosciences
Next MBX Biosciences earnings date
Q3 20266 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MBX Biosciences Inc. is a U.S.-based biotechnology company focused on developing precision medicines for endocrine disorders. The company’s research and development efforts target rare hormonal conditions, with a focus on creating peptide therapies that improve patient outcomes. Leveraging proprietary technology, MBX Biosciences aims to design therapies that address specific needs in endocrinology, including disorders related to hormone deficiencies or imbalances. The company advances its drug candidates through preclinical and clinical stages, seeking to bring effective treatments to patients with unmet medical needs. The company is headquartered in Carmel, Indiana, and its shares are listed on the NASDAQ.